Global Antibiotic Research and Development Partnership (GARDP)
The Global Antibiotic Research and Development Partnership (GARDP) is a not-for-profit organisation developing new treatments in the area of serious bacterial infections, with a focus on children and newborns, and sexually transmitted infections, such as gonorrhoea. Established by the World Health Organization (WHO) and the Drugs for Neglected Disease Initiative (DNDi) in 2016, GARDP is a core element of WHO’s Global Action Plan on Antimicrobial Resistance.
GARDP publishes calls for proposals on a dedicated webpage.
Please see below for more information about open opportunities.
- There are currently two funding opportunities available:
- Request for proposal for Clinical monitoring of the NeoSep1 part 2 clinical trial, in Africa, Middle East and Asia:
-
- Closing date: 26 March 2024
-
- Request for proposal for Services in synthetic chemistry, compound management, microbiology, in vitro drug metabolism and pharmacokinetics (DMPK) and toxicity:
-
- Closing date: 21 March 2024
-
Please refer to the Requests for proposals page for the anticipated future call for proposals.
Funding and licencing
Unknown
Unknown
Depending on the specific opportunity.
- If you are interested to receive complete documentation of the available RFPs, please send a request to: RFP_Procurement@gardp.org.
To connect with GARDP, please contact:
- GARDP Switzerland via email contact@gardp.org or by phone +41 22 555 19 90
- DNDi-GARDP South Africa via email dndi-gardp-southafrica@dndi.org
- GARDP North America via email info@gardpna.org